SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881108091595v1
23/7/814    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Martin, C.
Right arrow Articles by Smith, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, C.
Right arrow Articles by Smith, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial

CK Martin

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA corby.martin{at}pbrc.edu

H Han

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

SD Anton

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

FL Greenway

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

SR Smith

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

Abstract

The objective of this study was to identify mechanisms through which valproic acid (VPA) causes weight gain. Healthy participants (N = 52) were randomized to VPA or placebo in a double-blind study. Energy intake (EI) was measured in the laboratory at lunch and dinner, and physical activity (PA) was measured with accelerometry. Glucose levels and hormones [Peptide YY3–36, glucagon-like peptide-1 (GLP-1), leptin, ghrelin, insulin] that regulate EI were measured. Assessments occurred at baseline and week 3. Change from baseline was evaluated with mixed models ({alpha} = 0.05). Weight significantly increased in the VPA group (+0.49 kg), but not the placebo group. The VPA group increased fast food fats cravings and decreased glucose levels compared with placebo. Change in weight, EI and PA did not differ by group. Within group analyses indicated that the VPA group increased PA, hunger, binge eating, depression and GLP-1. VPA-associated weight gain is not likely due to changes in PA or the gut hormones studied. Although EI did not increase when measured after 3 weeks of treatment, VPA decreased glucose levels and increased motivation to eat; hence, EI might have increased in the short-term. Research testing VPA on short-term (1 week) EI, metabolism, and substrate partitioning is warranted.

Key Words: divalproex sodium • energy balance • energy expenditure • energy intake • food intake • physical activity • valproic acid • VPA • weight gain

This version was published on September 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 7, 814-825 (2009)
DOI: 10.1177/0269881108091595


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement